Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice of Revisions to Dividend Forecasts (Dividend Increase)
Shionogi, Last Fiscal Year Dividend Revised Upward by 4 yen
Shionogi Initiates New Drug Application Submission for Ensitrelvir for Post-Exposure Prophylaxis with the U.S. Food and Drug Administration
Shionogi Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Post-Exposure Prophylaxis of COVID-19.
Notice of Transition to Company with Audit and Supervisory Committee and the Candidates for Directors After the Transition
Late-Breaking at CROI 2025: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylax
Financial Results for the 3rd Quarter of FY2024 Supplement
Consolidated Finacial Results for the Third Quarter of Fiscal Year 2024 (IFRS)
3rd Quarter of Fiscal 2024 Finacial Results
Shionogi, Apr-Dec (Cumulative 3Q) Net Income Increases by 5%, Oct-Dec Net Income Increases by 38%
Shionogi Announces Positive Results from Phase 2 Trial of Respiratory Syncytial Virus Oral Antiviral Candidate S-337395
Acceptance of a New Drug Application for the COVID-19 Treatment, Ensitrelvir Fumaric Acid, in Taiwan and Conclusion of Government Stockpiling Contract
Shionogi Receives Award Through BARDA's RRPV to Advance Long-Acting Formulation of S-892216
Notice Regarding the Dissolution of Joint Ventures and Share Transfer Agreement with Ping An Insurance (Group) Company of China, Ltd.
Corporate Governance Report
Notice Regarding Actions to Achieve Management Conscious of Capital Costs and Stock Prices
Shionogi Announces Global Phase 3 Trial Demonstrates Post-Exposure Prophylactic Use of Ensitrelvir Prevents Symptomatic COVID-19
Notice of Revisions to Earnings Forecasts for the Fiscal Year Ending March 31, 2025
1st Half (Interim period) of Fiscal 2024 Financial Results
Financial Results for the Second Quarter of Fiscal Year 2024 <Supplement>